{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-002705","form_type":"8-K","ticker":"DFTX","cik":"0001813814","company_name":"Definium Therapeutics, Inc.","filed_at":"2024-01-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:25.642842+00:00","generated_at":"2026-06-07T02:31:19.559003+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"MindMed provides 2024 outlook; GAD Phase 2b showed 7.6-point HAM-A reduction, ADHD trial failed","bullets":["MM-120 100µg GAD: 7.6 HAM-A reduction vs placebo (p<0.0004, effect size 0.88); 78% response, 50% remission.","ADHD Phase 2a sub-perceptual dose trial failed primary endpoint; no further development for that regimen.","End-of-Phase 2 FDA meeting H1 2024; Phase 3 initiation expected H2 2024 for MM-120 in GAD.","Full 12-week Phase 2b results for MM-120 in GAD expected by Q1 2024 end.","Phase 1 for MM-402 (R(-)-MDMA) in ASD started Q4 2023; UHB MDMA trial topline data H1 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-002705","json":"https://secwatch.observer/filing/0000950170-24-002705.json","markdown":"https://secwatch.observer/filing/0000950170-24-002705.md","text":"https://secwatch.observer/filing/0000950170-24-002705.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1813814/000095017024002705/0000950170-24-002705-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1813814/000095017024002705/mnmd-20240108.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T02:31:19.559003+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}